Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual, White Superficial, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2024 - 2030

Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual, White Superficial, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2024 - 2030


Onychomycosis Market Growth & Trends

The global onychomycosis market size was estimated at USD 4.94 Billion in 2030 and is expected to grow at a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Onychomycosis Market Report Highlights
  • Distal subungual onychomycosis segment dominated the market in 2022 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
  • Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
  • Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
  • North America held the largest market share in 2022 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Type Segment
1.1.1.2. Treatment Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Primary Sources
1.11. List of Abbreviations
Chapter 2. Onychomycosis Market: Executive Summary
2.1. Market Snapshot
2.2. Type Snapshot
2.3. Treatment Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Onychomycosis Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Increasing Incidence of Onychomycosis
3.4.2. Rising Awareness About Treatment of Onychomycosis
3.4.3. Rising Awareness About Treatment of Onychomycosis
3.4.4. Growing Geriatric and Diabetic Populations
3.5. Market Restraint Analysis
3.5.1. Growing Geriatric and Diabetic Populations
3.6. Onychomycosis Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat of New Entrant
3.6.1.5. Competitive Rivalry
3.6.2. PESTLE Analysis
3.6.2.1. Political Landscape
3.6.2.2. Technological Landscape
3.6.2.3. Economic Landscape
3.6.3. Pricing Analysis
3.6.4. Pipeline Analysis
Chapter 4. Onychomycosis Market: Type Estimates & Trend Analysis
4.1. Global Onychomycosis Market: Type Segment Dashboard
4.2. Global Onychomycosis Market: Type Movement Analysis
4.3. Global Onychomycosis Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Distal Subungual Onychomycosis
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. White Superficial Onychomycosis
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.6. Proximal Subungual Onychomycosis
4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.7. Other Types
4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Onychomycosis Market: Treatment Estimates & Trend Analysis
5.1. Global Onychomycosis Market: Treatment Segment Dashboard
5.2. Global Onychomycosis Market: Treatment Movement Analysis
5.3. Global Onychomycosis Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
5.4. Oral
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Topical
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Regional Market Dashboard
6.2. Global Regional Market Snapshot
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. U.S.
6.4.1.1. Key Country Dynamics
6.4.1.2. Competitive Scenario
6.4.1.3. Regulatory Framework/Reimbursement Framework
6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.2. Canada
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework/Reimbursement Framework
6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key Country Dynamics
6.5.1.2. Competitive Scenario
6.5.1.3. Regulatory Framework/Reimbursement Framework
6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.2. Germany
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework/Reimbursement Framework
6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.3. Spain
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework/Reimbursement Framework
6.5.3.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework/Reimbursement Framework
6.5.4.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework/Reimbursement Framework
6.5.5.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.6. Denmark
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework/Reimbursement Framework
6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework/Reimbursement Framework
6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.8. Norway
6.5.8.1. Key Country Dynamics
6.5.8.2. Competitive Scenario
6.5.8.3. Regulatory Framework/Reimbursement Framework
6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key Country Dynamics
6.6.1.2. Competitive Scenario
6.6.1.3. Regulatory Framework/Reimbursement Framework
6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.2. China
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework/Reimbursement Framework
6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.3. India
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework/Reimbursement Framework
6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.4. South Korea
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework/Reimbursement Framework
6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework/Reimbursement Framework
6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Competitive Scenario
6.6.6.3. Regulatory Framework/Reimbursement Framework
6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key Country Dynamics
6.7.1.2. Competitive Scenario
6.7.1.3. Regulatory Framework/Reimbursement Framework
6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7.2. Mexico
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework/Reimbursement Framework
6.7.2.4. Mexico Onychomycosis Market, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework/Reimbursement Framework
6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key Country Dynamics
6.8.1.2. Competitive Scenario
6.8.1.3. Regulatory Framework/Reimbursement Framework
6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key Country Dynamics
6.8.2.2. Competitive Scenario
6.8.2.3. Regulatory Framework/Reimbursement Framework
6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.3. UAE
6.8.3.1. Key Country Dynamics
6.8.3.2. Competitive Scenario
6.8.3.3. Regulatory Framework/Reimbursement Framework
6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key Country Dynamics
6.8.4.2. Competitive Scenario
6.8.4.3. Regulatory Framework/Reimbursement Framework
6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company /Competition Categorization
7.2. Participant Overview
7.3. Financial Performance
7.4. Product Overview
7.5. Company Market Share Analysis
7.6. Strategy Mapping, 2023
7.6.1. Bausch Health Companies Inc.
7.6.1.1. Overview
7.6.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.1.3. Product Benchmarking
7.6.1.4. Strategic Initiatives
7.6.2. GSK plc.
7.6.2.1. Overview
7.6.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.2.3. Product Benchmarking
7.6.2.4. Strategic Initiatives
7.6.3. Abbott
7.6.3.1. Overview
7.6.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.3.3. Product Benchmarking
7.6.3.4. Strategic Initiatives
7.6.4. Pfizer, Inc.
7.6.4.1. Overview
7.6.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.4.3. Product Benchmarking
7.6.4.4. Strategic Initiatives
7.6.5. Bayer AG
7.6.5.1. Overview
7.6.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.5.3. Product Benchmarking
7.6.5.4. Strategic Initiatives
7.6.6. Teva Pharmaceutical Industries Ltd.
7.6.6.1. Overview
7.6.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.6.3. Product Benchmarking
7.6.6.4. Strategic Initiatives
7.6.7. Cipla Inc.
7.6.7.1. Overview
7.6.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.7.3. Product Benchmarking
7.6.7.4. Strategic Initiatives
7.6.8. Merck & Co., Inc.
7.6.8.1. Overview
7.6.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.8.3. Product Benchmarking
7.6.8.4. Strategic Initiatives
7.6.9. Novartis AG
7.6.9.1. Overview
7.6.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.9.3. Product Benchmarking
7.6.9.4. Strategic Initiatives
7.6.10. Sun Pharmaceutical Industries Ltd.
7.6.10.1. Overview
7.6.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.10.3. Product Benchmarking
7.6.10.4. Strategic Initiatives
7.6.11. Moberg Pharma AB
7.6.11.1. Overview
7.6.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.11.3. Product Benchmarking
7.6.11.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings